Our experts on proteomics and signal transduction
Max Planck Institute of Biochemistry
Am Klopferspitz 18
82152 Martinsried
GERMANY
Website

Team Leader

Prof. Dr. Matthias Mann
Principal Investigator
Phone: +49 89 857 825 57
Send message

Team Members

Dr. Philipp Geyer
Postdoc
Phone: +49 89 857 825 40
Send message
Dr. Felix Meissner
Group Leader
Phone: +49 89 857 825 67
Send message
Peter Treit
Researcher
Phone: +49 89 857 825 40
Send message

Institute Presentation

The Department of Proteomics and Signal Transduction of the Max-Planck Institute of Biochemistry, headed by Prof. Matthias Mann, was established in 2005. Matthias Mann is the highest-cited German researcher with an h-index of more than 200 and more than 200,000 citations (Google Scholar). Matthias Mann is a pioneer of mass spectrometry-based proteomics and has made landmark contributions to the development of the electrospray ionization technology (awarded the Noble Prize for Prof. Dr. Mann’s thesis advisor John Fenn in 2002). This work has made mass spectrometry applicable to molecular biology. He has developed computer algorithms to connect mass spectrometric data with sequence databases and downstream biology. Another development of equal impact has been the introduction of quantitation into proteomics, as well as the rigorous statistical treatment of peptide and protein identification results. The department works in proteomics technology development and performs global large-scale proteomic and phosphoproteomic studies in different biological questions and medical fields.

The Mann laboratory is a leader in the technology and application of mass spectrometry-based proteomics and has pushed its boundaries for deepest coverage of proteomes for over two decades. Recently the group has increasingly focussed on clinically relevant topics, especially the analysis of the blood proteome. The group´s technological developments streamlined the extensive proteomics workflow to an automated high-throughput pipeline, which allows the analysis of thousands of plasma samples. The possibility to screen large clinical cohorts enables the development new concepts for proteomics-based biomarker research like the rectangular workflow (deep coverage of both discovery and validation cohorts) for biomarker discovery and the idea of a large knowledge base that includes protein changes across many human health and disease states. Follow the Mann lab on Twitter @labs_mann.